User profiles for Xiaoming Yang

yang xiaoming

soochow university
Verified email at suda.edu.cn
Cited by 4587

Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials

…, X Yang, L Zhang, L Huang, Q Wang, J Lu, Y Yang… - Jama, 2020 - jamanetwork.com
… Wang, Yuan, Shen, and Xiaoming Yang reported receiving grants from the Ministry of
Science and Technology of the People’s Republic of China during the conduct of the study. Drs …

[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

…, X Yang, Y Liu, Q Wang, L Huang, Y Yang… - The Lancet infectious …, 2021 - thelancet.com
Background The ongoing COVID-19 pandemic warrants accelerated efforts to test vaccine
candidates. We aimed to assess the safety and immunogenicity of an inactivated severe …

Well-dispersed chitosan/graphene oxide nanocomposites

X Yang, Y Tu, L Li, S Shang, X Tao - ACS applied materials & …, 2010 - ACS Publications
Nanocomposites of chitosan and graphene oxide are prepared by simple self-assembly of
both components in aqueous media. It is observed that graphene oxide is dispersed on a …

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

…, W Zhang, X Zheng, Y Liu, H Yang… - Proceedings of the …, 2020 - National Acad Sciences
Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019
(COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were …

Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial

N Al Kaabi, Y Zhang, S Xia, Y Yang, MM Al Qahtani… - Jama, 2021 - jamanetwork.com
Importance Although effective vaccines against COVID-19 have been developed, additional
vaccines are still needed. Objective To evaluate the efficacy and adverse events of 2 …

[HTML][HTML] Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2

…, Z Lou, M Xu, C Qin, G Wu, GF Gao, W Tan, X Yang - Cell, 2020 - cell.com
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a …

[HTML][HTML] The draft genome of sweet orange (Citrus sinensis)

…, S Xiao, MK Biswas, W Zeng, F Guo, H Cao, X Yang… - Nature …, 2013 - nature.com
Oranges are an important nutritional source for human health and have immense economic
value. Here we present a comprehensive analysis of the draft genome of sweet orange (…

[HTML][HTML] Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase …

…, YT Zhang, YX Wang, H Wang, YK Yang… - The Lancet Infectious …, 2022 - thelancet.com
Background Although SARS-CoV-2 infection often causes milder symptoms in children and
adolescents, young people might still play a key part in SARS-CoV-2 transmission. An …

Progress of zinc oxide‐based nanocomposites in the textile industry

…, S Zhang, W Zhang, X Yang - IET Collaborative …, 2021 - Wiley Online Library
Textile materials have been enriched in function at the composite level with continuous
developments in the textile industry. Zinc oxide (ZnO) nanoparticles (ZnO‐NPs) are strongly …

Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements

CJ Huang, H Lin, X Yang - Journal of Industrial Microbiology and …, 2012 - academic.oup.com
Nearly 30% of currently approved recombinant therapeutic proteins are produced in Escherichia
coli. Due to its well-characterized genetics, rapid growth and high-yield production, E. …